Essilor has released one year findings on Stellest spectacle lenses for myopia control, and reported the launch of the lens in China.
Stellest was designed with an exclusive technology called ‘H.A.L.T.’ (Highly Aspherical Lenslet Target) by Essilor’s industry-leading research and development teams.
Interim results after one year of an ongoing three-year clinical trial of the lens, on 167 myopic children aged between 8 and 13 years old, revealed: children wearing Stellest lenses saved more than half a diopter of myopia degree on average (more than 60% slow-down in myopia progression compared to the control group wearing single vision lenses); eye elongation was prevented in 28% of the children wearing Stellest lenses, while eye elongation occurred in all the children wearing single vision lenses; and 100% of children wearing Stellest lenses had clear vision, adapted to their new lenses within a week, and were as satisfied with their quality of vision as the children wearing single vision lenses.
Essilor launched Stellest lens in the Wenzhou Medical University Eye Hospital in China in July. A broader roll-out will be completed via other hospitals in China, followed by several other countries.